.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
McKesson
Cerilliant
US Army
Federal Trade Commission
US Department of Justice
Cipla
QuintilesIMS
McKinsey
Julphar

Generated: September 25, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 012703

« Back to Dashboard
NDA 012703 describes ELAVIL, which is a drug marketed by Astrazeneca and is included in two NDAs. Additional details are available on the ELAVIL profile page.

The generic ingredient in ELAVIL is amitriptyline hydrochloride. There are thirteen drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the amitriptyline hydrochloride profile page.

Summary for NDA: 012703

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Antidepressants
Formulation / Manufacturing:see details

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength10MG
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:Yes

Summary for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength25MG
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:Yes

Summary for product number 004

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength50MG
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:Yes

Expired Orange Book Patents for NDA: 012703

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca
ELAVIL
amitriptyline hydrochloride
TABLET;ORAL012703-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Astrazeneca
ELAVIL
amitriptyline hydrochloride
TABLET;ORAL012703-005Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Astrazeneca
ELAVIL
amitriptyline hydrochloride
TABLET;ORAL012703-004Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Astrazeneca
ELAVIL
amitriptyline hydrochloride
TABLET;ORAL012703-006Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Astrazeneca
ELAVIL
amitriptyline hydrochloride
TABLET;ORAL012703-003Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Astrazeneca
ELAVIL
amitriptyline hydrochloride
TABLET;ORAL012703-007Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Federal Trade Commission
Farmers Insurance
Express Scripts
Cipla
Merck
Fish and Richardson
Deloitte
Baxter
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot